Document Detail


Long-term effectiveness of ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.
MedLine Citation:
PMID:  21893390     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: We performed this study to evaluate the long-term efficacy and tolerability of ethosuximide (ESX), valproic acid (VPA), and lamotrigine (LTG) as initial monotherapies for patients with newly diagnosed childhood absence epilepsy.
METHODS: We retrospectively reviewed the medical records of 128 patients (45 boys and 83 girls) diagnosed with childhood absence epilepsy at the Seoul National University Hospital. The diagnosis was based on the criteria proposed by Panayiotopoulos in 2005. We measured the seizure-free rate and the retention rate observed during 2 years of treatment. Follow-up electroencephalography (EEG), any reported adverse events, and reasons for antiepileptic drug (AED) discontinuation were reviewed.
RESULTS: The seizure-free rate of ESX (84%) was significantly higher than that of VPA (62%) and LTG (53%) at 3 months. The seizure-free rate of ESX (90%) was significantly higher than that of LTG (63%) at 6 months. After 9 months, there was no significant difference in seizure-free rate among the three groups. There were no significant differences among the three groups in terms of normalization of EEG at 12 months (ESX, 77%; VPA, 83%; and LTG, 64%), retention rate throughout the whole treatment period, and adverse-event rates (ESX, 25%; VPA, 29%; and LTG, 14%).
CONCLUSION: This study suggests that ESX, VPA, and LTG are equally effective in the long-term treatment of newly diagnosed CAE patients. However, the onset of efficacy was faster for ESX compared with VPA or LTG. Efficacy, tolerability, and adverse event profiles should be carefully considered when selecting AEDs to treat individual patients with CAE.
Authors:
Hee Hwang; Hunmin Kim; Seung Hyo Kim; Se Hee Kim; Byung Chan Lim; Jong-Hee Chae; Ji Eun Choi; Ki Joong Kim; Yong Seung Hwang
Publication Detail:
Type:  Journal Article     Date:  2011-09-03
Journal Detail:
Title:  Brain & development     Volume:  34     ISSN:  1872-7131     ISO Abbreviation:  Brain Dev.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-23     Completed Date:  2012-08-20     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  7909235     Medline TA:  Brain Dev     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  344-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.
Affiliation:
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea. neuroandy@korea.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Anticonvulsants / adverse effects,  therapeutic use*
Child
Child, Preschool
Electroencephalography
Epilepsy, Absence / drug therapy*
Ethosuximide / adverse effects,  therapeutic use*
Female
Follow-Up Studies
Humans
Male
Retrospective Studies
Treatment Outcome
Triazines / adverse effects,  therapeutic use*
Valproic Acid / adverse effects,  therapeutic use*
Young Adult
Chemical
Reg. No./Substance:
0/Anticonvulsants; 0/Triazines; 77-67-8/Ethosuximide; 99-66-1/Valproic Acid; U3H27498KS/lamotrigine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Novel V97G ASAH1 mutation found in Farber disease patients: Unique appearance of the disease with an...
Next Document:  Review of MRI Technique and imaging findings in athletic pubalgia and the "sports hernia"